🇺🇸 MOR03087 in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 12

Most-reported reactions

1. Malignant Melanoma — 2 reports (16.67%)
2. Pneumonia — 2 reports (16.67%)
3. Acute Kidney Injury — 1 report (8.33%)
4. Atrial Flutter — 1 report (8.33%)
5. Basal Cell Carcinoma — 1 report (8.33%)
6. Breast Cancer — 1 report (8.33%)
7. Cardiovascular Disorder — 1 report (8.33%)
8. Erysipelas — 1 report (8.33%)
9. Febrile Neutropenia — 1 report (8.33%)
10. Malignant Sweat Gland Neoplasm — 1 report (8.33%)

Source database →

Frequently asked questions

Is MOR03087 approved in United States?

MOR03087 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for MOR03087 in United States?

MorphoSys AG is the originator. The local marketing authorisation holder may differ — check the official source linked above.